Side-by-side · Research reference

PancragenvsSemaglutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited

BFDA-ApprovedFlagship15/53 cited

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

Pancragen

Semaglutide

Primary target

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Pathway

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

Downstream effect

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Feedback intact?

Yes — preserves physiological glucose-insulin response

Glucose-dependent insulin release preserves physiological feedback

Origin

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Antibody development

—

02Dosage Protocols

Parameter

Pancragen

Semaglutide

Primate dose (rhesus macaque)

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

—

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

—

Route

IntramuscularGoncharova 2015

—

Frequency

Once daily for 10 daysGoncharova 2014

Once weekly, same day each week

Treatment cycle

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

—

Evidence basis

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

Diabetes model

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

—

Standard dose (T2D, Ozempic)

—

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

Standard dose (weight, Wegovy)

—

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

Titration schedule

—

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

Duration

—

Indefinite for chronic indication

Discontinuation results in weight regain.

Reconstitution

—

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Timing

—

Any time of day, with or without food

Half-life

—

~7 days (168 h)WEGOVY (semaglutide) injection 2021

04Side Effects & Safety

Parameter

Pancragen

Semaglutide

Reported adverse events

None documented in primate studies

—

Tolerability

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

—

Human safety data

No published human trials; clinical use limited to Russian gerontology protocols

—

GI symptoms

—

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Injection site reaction

—

Mild erythema, pruritus

Pancreatitis risk

—

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

Hypoglycemia

—

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

ContraindicatedWEGOVY (semaglutide) injection 2021

Heart rate

—

Modest ↑ resting HR (~2-4 bpm)

Absolute Contraindications

Pancragen

—

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Relative Contraindications

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

05Administration Protocol

Parameter

Pancragen

Semaglutide

1. Reconstitution

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

2. Route

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

3. Timing

No specific timing constraints documented. Administered once daily in primate protocols.

Once weekly, same day. Day can be changed if ≥2 days separate doses.

4. Cycle structure

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

5. Needle

—

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

06Stack Synergy

Pancragen

— no documented stacks

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)